Abstract: Despite the finding that rtL180M and rtM204V/I were higher among ART-experienced individuals, the overall prevalence of DRMs (48.0% versus 36.4%) showed no significance difference among antiretroviral therapy (ART) status.
Abstract: Lamivudine selected DRMs, that is, rtL180M (29.3%) and rtM204V/I (29.3%) and rtV173L (15.5%) were more prevalent in HBV-HIV-coinfected individuals but absent in HBV-monoinfected individuals.
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRM
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Discussion: In our study, twenty (95.2%) of the 21 patients had at least one mutation that may confer clinical resistance to both telbivudine (rtM204V/I) and 3TC (rt180M + rtM204V/I, rtV173L + rtL180M + rtM204V/I, and rtL80I + rtM204I).
Discussion: The 3TC mutations rtL80I, rtV173L, PMID: 27919846
2016
Hepatobiliary & pancreatic diseases international
1Abstract: DATA SOURCES: PubMed and Web of Science were searched using terms: ""hepatitis B virus"", ""HBV drug resistance mutation"", ""HBV surface protein"", ""HBV truncation"", ""hepatocellular carcinoma"", ""rtA181T/sW172*"", ""rtM204I/sW196*"", ""rtV191I/sW182*"", and relevant articles published in English in the past decades were reviewed."
Abstract: RESULTS: The rtA181T/s
Monitoring of genotypic resistance profile in chronic hepatitis B patients receiving nucleos(t)ide analogues in Huzhou, China.
PMID: 27694733
2016
Journal of infection in developing countries
Abstract: Among patients who harbored rtM204 combination mutations, rtM204I and rtM204V were significantly associated with rtL80I/V and rtL180M, respectively.
Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos(t)ide analogue drugs treatment by ultra-deep pyrosequencing.
Result: At baseline, patient 2 harbored the rtA181T (4.7%), rtN236T (5.7%), rtL180M (12.5%), rtS202G (3.2%), and rtM204I/V (7%) substitutions, and other resistance mutations were present at low levels (<1%).
Result: At baseline, this patient carried with rtL180M (2.4%), rtM204I/V (3.4%), rtS202G (3.3%), rtA181V/T (4.7%), and
Compensatory variances of drug-induced hepatitis B virus YMDD mutations.
Abstract: The data showed different compensatory changes followed by the rtM204I/V.
Introduction: Recently, more and more research works illustrate that YMDD variation is not a single mutation of rtM204I/V in the RT, but companied by compensatory mutation, such as rtL180M, etc.
Introduction: The typical YMDD motif variation (rtM204I/V) could be found in the reverse transcriptase (RNA-dependent DNA polymerase, RT) from all the genotypes, after the patients with PMID: 27581951
2016
Journal of virological methods
Abstract: The rtA181V, rtM204V/I, rtN236T and, rtM250V are high prevalent mutations found in the drug-resistant HBV strains.
Mutational analysis of reverse transcriptase and surface proteins of patients with partial virological response during mono and combination antiviral therapies in genotype D chronic hepatitis B.
Abstract: T54N, L80I/V, I91L/V, L180M, M204I/V, Q215P/S, and F221Y/S showed the highest number of mutations in all groups with different frequencies.
Discussion: It is interesting to note that mutants L180M and M204I that were detected during LAM and ADV breakthrough showed a high prevalence in the LAM-only group (25 and 50%, respectively), followed by a low frequency in the ADV-only group (9.9 and 23%, respectively), whereas they showed a very high frequency in group III in which the patients received ADV after LAM breakthrough (43.75 and 68.75%, respectively).
Discussion: Studies showed that the failure of therapy due to PMID: 27492206
2016
The Kobe journal of medical sciences
Abstract: The known rtM204I mutation was the most frequent in both groups.
[Effect of Telbivudine Tablet Combined Jianpi Bushen Recipe on HBV Specific Cytotoxic T Lymphocyte and HBeAg Seroconversion in Patients with HBeAg Positive Chronic Hepatitis B].
PMID: 27386641
2016
Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi
Abstract: rtM204I variation occurred in 1 case (2.22%) of the treatment group and 2 cases (4.44%) in the control group.
HBV mutation literature information.
PMID: 
2017
Antiviral therapy
Browser Board
Co-occurred Entities
Filtrator
ViMRT